Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas

Clinical Cancer Research

Volumn 11, Issue 14, 2005, Pages 5167-5174

  Brell, Marta ^a   Tortosa, Avelina ^d   Verger, Eugenia ^e   Gil, Juan Miguel ^b   Viñolas, Nuria ^e   Villá, Salvador ^b   Acebes, Juan José ^a   Caral, Lluis ^e   Pujol, Teresa ^e   Ferrer, Isidro ^c   Ribalta, Teresa ^e   Graus, Francesc ^e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c Institut de Neuropatologia   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; ADOLESCENT; BIOSYNTHESIS; BRAIN TUMOR; FOLLOW UP; GENE EXPRESSION PROFILING; GENETICS; GLIOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS;

EID: 22344447421     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0230     Document Type: Article

References (51)

1. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 2002; 359:1011-8.
2. Cavenee WK, Furnari FB, Nagane M, et al. Astrocytic tumors. In: Kleihues P, Cavenee WK, editors. Pathology and genetics. Tumours of the nervous system. Lyon: IARC Press; 2000. p. 27-9.
3. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30:10-4.
4. Tortosa A, Viñolas N, Villà S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003;97: 1063-71.
5. 6- methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br J Cancer 2002;86:1888-92.
6. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-7.
7. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;16:3310-5.
8. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167-223.
9. 6- methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1- nitrosourea in human brain tumor-derived cell lines. Mol Carcinog 1995; 13:81-8.
10. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 1993;53:3416-20.
11. Baylin SB, Herman JG. DNA hypermethylation intumorigenesis: epigenetic joins genetics. Trends Genet 2000;16:168-73.
12. 6-methylguanine-DNA methyltransferase gene expression in gliomas by means of real-time quantitative RT-PCR and clinical response to nitrosoureas. Int J Cancer 2003; 103:67-72.
13. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 1998; 58:1068-73.
14. Weinstein JN. Pharmacogenomics: teaching old drugs new tricks. N Engl J Med 2000;343:1408-9.
15. Paz MF, Fraga MF, Avila S, et al. A systematic profile of DNA methylation in human cancer cell lines. Cancer Res 2003;63:1114-21.
16. 6- methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)-methyl-3-(2-chloroethyl)-3-nitrosourea- based chemotherapy. Neurosurgery 2004;52:349-57.
17. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
18. 6-metylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with Temozolamide. Clin Cancer Res 2004;10:1871-4.
19. 6-methylguanine- DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to Temozolamide plus Cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9:1461-8.
20. 6-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer 1996;69:420-5.
21. 6- methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation. Int J Cancer 1999;416:416-20.
22. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to Temozolamide in primary gliomas. Clin Cancer Res 2004;10:4933-8.
23. Andersson U, Malmer B, Bergenheim AT, Brännström T, Henriksson R. Heterogeneity in the expression of markers for drug resistance in brain tumors. Clin Neuropathol 2004;23:21-7.
24. Belanich M, Pastor M, Randall T et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56:783-8.
25. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res 1999; 5:807-14.
26. 6-methylguanine DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 1999;26:104-9.
27. 6-methylguanine-DNA methyltransferase, glutathione-S-transferase π in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis. Neurol Res 2003;25:241-8.
28. 6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2004;113:581-7.
29. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMTgene in oligodendroglial tumors. Int J Cancer 2005;113:379-85.
30. 6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas. J Neurooncol 2004;70: 333-40.
31. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-80.
32. Montori VM, Guyatt GH. Intention-to-treat principle. Can Med Assoc J 2001;165:1339-41.
33. Blanc JL, Wager M, Guilhot J, et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004;68: 275-83.
34. 6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003;13:176-84.
35. 6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy. Carcinogenesis 1996;17:637-41.
36. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003;24:625-35.
37. 6-methylguanine-DNA methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer 2003;89:1517-23.
38. Rood BR, Zhang H, Cogen PH. Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro-oncol 2004;6: 200-7.
39. 6-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 2001;92:2760-8.
40. Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF. Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J Biol Chem 1996;271: 13916-24.
41. 6-methylguanine-DNA methyltransferase (MGMT) geneintesticular cancer. Oncogene 2002;21:8878-84.
42. Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol (Berl) 2003;106:479-85.
43. Cameron EE, Baylin SB, Herman JG. p15 (INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 1999;94: 2445-51.
44. Lenz G, Hutter G, Hiddemann W, Dreyling M. Promoter methylation and expression of DNA repair genes hMLH1 and MGMT in acute myeloid leukemia. Ann Hematol 2004;83:628-33.
45. Bearzatto A, Szadkowski M, Macpherson P, Jiricny J, Karran P. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 2000;60: 3262-70.
46. 6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis 2003;24:1337-45.
47. 6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 1994;269. 17228-37.
48. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4: 296-307.
49. 6-methylguanine DNA methyltransferase in human cancer Oncogene 2004;23:1-8.
50. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
51. 6-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002;9:371-9.